These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 35740909)

  • 1. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
    Rodríguez F; Caruana P; De la Fuente N; Español P; Gámez M; Balart J; Llurba E; Rovira R; Ruiz R; Martín-Lorente C; Corchero JL; Céspedes MV
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
    Agarwal V; Bajpai M; Sharma A
    Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell surface-nanoengineering for cancer targeting immunoregulation and precise immunotherapy.
    Wang Y; Huang G; Hou Q; Pan H; Cai L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(4):e1875. PubMed ID: 36567668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-delivered Therapeutic Agents Targeting the Tumor Microenvironment for Antitumor Therapy.
    Li XT; Peng H; He J; Zhang Z; Gan L; Wu P; Zhong L; Zhao Y; Deng Z; Huang Y
    Discov Med; 2021; 32(166):93-107. PubMed ID: 35219350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-sensitive nano-systems for drug delivery in cancer therapy.
    Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
    Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery.
    Xie X; Zhang Y; Li F; Lv T; Li Z; Chen H; Jia L; Gao Y
    Curr Cancer Drug Targets; 2019; 19(4):257-276. PubMed ID: 29956629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment.
    Li J; Zhu L; Kwok HF
    Drug Resist Updat; 2023 Jan; 66():100904. PubMed ID: 36462375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
    Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
    Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.
    Haider M; Elsherbeny A; Pittalà V; Consoli V; Alghamdi MA; Hussain Z; Khoder G; Greish K
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges.
    Tramontano C; De Stefano L; Rea I
    Mar Drugs; 2023 Apr; 21(5):. PubMed ID: 37233460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of nanotechnology for the treatment of cancer: Recent advances.
    Klochkov SG; Neganova ME; Nikolenko VN; Chen K; Somasundaram SG; Kirkland CE; Aliev G
    Semin Cancer Biol; 2021 Feb; 69():190-199. PubMed ID: 31446004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor physiology and delivery of nanopharmaceuticals.
    Campbell RB
    Anticancer Agents Med Chem; 2006 Nov; 6(6):503-12. PubMed ID: 17100555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions.
    Raj R; Mongia P; Kumar Sahu S; Ram A
    Curr Drug Targets; 2016; 17(2):206-28. PubMed ID: 26201484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.